Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.40 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30687784 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1SSTR5DDR1DRD3 | |
| SCHEMBL26682854 | 0.92 | SSTR5 (0.44) | CHRM2CHRM1SSTR5DDR1DRD3 | |
| SCHEMBL26680977 | 0.90 | CHRNA10 (0.41) | DRD3DRD2DRD4CHRNA10CHRNA9 | |
| SCHEMBL26682995 | 0.89 | CHRM3 (0.46) | CHRM2CHRM1DDR1DRD3DRD2 | |
| SCHEMBL30687743 | 0.89 | CHRM3 (0.46) | CHRM2CHRM1DDR1DRD3DRD2 | |
| SCHEMBL26682606 | 0.88 | TP53 (0.43) | DRD3DRD2DRD4CHRNA10CHRNA9 | |
| SCHEMBL26681006 | 0.88 | DRD3 (0.44) | DDR1DRD3DRD2DRD4CHRM4 | |
| SCHEMBL30687571 | 0.88 | DRD3 (0.44) | DDR1DRD3DRD2DRD4CHRM4 | |
| SCHEMBL26682169 | 0.88 | CHEK1 (0.45) | SSTR5DDR1DRD3DRD2DRD4 | |
| SCHEMBL26680403 | 0.87 | DRD2 (0.45) | SSTR5DRD3DRD2DRD4CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | CHRM2 3030/4885CHRM1 3262/4885SSTR5 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.